JWM
LGND icon

JPL Wealth Management’s Ligand Pharmaceuticals LGND Stock Holding History

JPL Wealth Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$77.8K Hold
246
– – 0.02% 200
2026
Q1 		$49.1K Buy
+246
New +$48.7K 0.01% 244
2025
Q4 		– Sell
-296
Closed -$52.4K – 668
2025
Q3 		$52.4K Buy
+296
New +$44K 0.01% 245

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JPL Wealth Management's LGND Position: Q2 2026 in Review

JPL Wealth Management held its Ligand Pharmaceuticals (LGND) position steady in Q2 2026 at 246 shares worth $77.8K. The position accounts for 0.02% of the portfolio, ranked #200.

JPL Wealth Management first reported a position in LGND in Q3 2025 and has held it in 3 quarters since. 417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • JPL Wealth Management held 246 shares of Ligand Pharmaceuticals worth $77.8K as of Q2 2026.
  • JPL Wealth Management left its Ligand Pharmaceuticals share count unchanged in Q2 2026.
  • Ligand Pharmaceuticals made up 0.02% of JPL Wealth Management's portfolio in Q2 2026, its #200 holding.
  • JPL Wealth Management first reported a position in Ligand Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on JPL Wealth Management's 13F filing for Q2 2026, filed 14 Aug 2026.